Study evaluates treatment with troriluzole in patients with hereditary spinocerebellar ataxias

Researchers have reported promising results from Phase IIb/III trials examining the long-term effects of BHV-4157-201, or troriluzole, on hereditary spinocerebellar ataxias (SCAs) – potentially fatal, rare neurodegenerative disorders affecting the cerebellum.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.